Web2 days ago · Annovis, led by founder and CEO Maria Maccecchini, said the additional capital will fund the company's two ongoing clinical trials of its new drug candidate buntanetap. A phase 3 study is testing ... WebSep 8, 2024 · BERWYN, Pa., Sept. 8, 2024 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company …
Maria-Luisa Maccecchini Biography and Net Worth
WebDec 20, 2024 · Maria Maccecchini, Ph.D. Founder, President and Chief Executive Office, Annovis Bio, Inc. Forward-Looking Statements Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. WebOct 11, 2024 · Maria-Luisa Maccecchini has not been actively trading shares of Annovis Bio over the course of the past ninety days. Most recently, on Monday, October 11th, Maria-Luisa Maccecchini bought 18,000 shares of Annovis Bio stock. The stock was acquired at an average cost of $27.61 per share, with a total value of $496,980.00. email server settings cox
NextUp: Annovis Bio Is Unlocking the Mysteries of Brain …
WebMar 22, 2024 · Dr. Maccecchini’s background and how it led her to the founding of Annovis Bio? How she transitioned from academia to biosciences. An overview of Annovis Bio’s approach and its lead compound? The data of the Buntanetap studies for Parkinson’s and Alzheimer’s. The biggest challenges in working with neurodegenerative diseases like … WebJun 30, 2024 · Dr. Maria Maccecchini has over 65 patents, many of them focused on neurodegenerative diseases. Dr. Maccecchini’s career includes a PhD in biochemistry from the Biocenter of Basel and two... WebMay 28, 2024 · May 28, 2024, 2:22 PM. Maria Maccecchini, Annovis CEO, joins Yahoo Finance Live to discuss the company’s positive Alzheimer’s drug study. ford rapid fit leeds